Hana Tour (039130)
Korea Stock Exchange · Korea · prices in KRW · close of 19 Oct 2026
Key indicators
| Last close | KRW 29,400.00 |
|---|---|
| 52-week range | 28,250.00 – 51,500.00 |
| Return, 1 month / 3 months | −11.8% / −4.1% |
| Return, 1 year / 3 years | −40.0% / −29.9% |
| Trend | Below its 200-day average |
| RSI (14) | 41 |
| Volatility (1 year) | 35.0% |
| Worst drawdown (1 year) | -44.0% |
| Average daily value traded | 863.55M KRW |
| Dividend yield | 4.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Hana Tour is a South Korean travel company that arranges package tours, flights and accommodation for travellers heading abroad, along with related travel agency services. It serves individual holidaymakers and groups through a network of branches and online booking channels, and it also handles corporate and incentive travel. The company is based in Korea and focuses mainly on outbound tourism, helping customers plan and book trips to destinations outside the country.
Hana Tour trades under the code 039130 on the Korea Stock Exchange in Korea, with its price quoted in South Korean won (KRW). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Hana Tour (039130) trades on the Korea Stock Exchange in Korea. It last closed at KRW 29,400.00 on 19 October 2026.
Its price-based Market X-Ray is 41 out of 100 (a weak price profile), ranking 652 of 934 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 40.0% and over the last three months it fell 4.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Korea Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 25 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -23.1% | ||
| From 52-week high | -42.5% | ||
| Momentum | 25 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -4.1% | ||
| 6-month return | -28.6% | ||
| 12-month return, skipping the last month | -31.9% | ||
| Stability (higher is calmer) | 64 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 35.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -44.0% | ||
| Liquidity | 56 · Fair | Moderate trading activity. | |
| Average daily value traded | 863.55M KRW | ||
| Zero-volume days | 0.0% | ||
| Income | 36 · Weak | Dividend is small or irregular. | |
| Dividend yield | 4.1% | ||
| Years with dividends | 3 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.5% |
|---|---|
| 1 month | −11.8% |
| 3 months | −4.1% |
| 6 months | −28.6% |
| 1 year | −40.0% |
| 3 years | −29.9% |
| 5 years | – |
Signals
| 50-day / 200-day average | 31,424.00 / 38,246.89 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 802.18 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Jan 2026 | KRW 1,200.0000 |
| 7 Jan 2025 | KRW 2,300.0000 |
| 1 Apr 2024 | KRW 5,000.0000 |
| 29 Dec 2020 | KRW 414.8705 |
| 29 Jun 2020 | KRW 622.3058 |
| 27 Dec 2019 | KRW 400.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Korea Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.